GlassScriptPhysician profile
John Edward Robinton
NPI 1750321725
$4,050.71
in general payments reported to CMS, 2019-2025
33 companies · $679 in 2025
The $679 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $312 · 2021: $391 · 2022: $820 · 2023: $643 · 2024: $746 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.90 | 2020-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $554.30 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $535.48 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $490.26 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $336.99 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $186.14 | 2022 | |
| Eisai INC. | $177.91 | 2022-2025 | |
| Biogen, INC. | $89.79 | 2020-2024 | Tysabri, Vumerity, Leqembi |
| Amgen INC. | $81.15 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $66.75 | 2020-2021 | |
| Emd Serono, INC. | $65.90 | 2022-2023 | Mavenclad |
| Arbor Pharmaceuticals, INC. | $60.01 | 2019-2022 | |
| Argenx US, INC. | $57.35 | 2022-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $45.45 | 2022-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $43.48 | 2019-2024 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $39.67 | 2019 | |
| Grifols USA, LLC | $35.10 | 2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $31.14 | 2022 | |
| Oyster Point Pharma, INC. | $30.72 | 2024 | Tyrvaya |
| Currax Pharmaceuticals LLC | $28.07 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $27.52 | 2021 | |
| Genzyme Corporation | $26.69 | 2019 | |
| Allergan, INC. | $25.21 | 2020 | |
| Acadia Pharmaceuticals INC | $16.98 | 2024 | Nuplazid |
| Genentech USA, INC. | $16.53 | 2025 | Ocrevus Zunovo |
| Aerie Pharmaceuticals, INC. | $15.00 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Impel Pharmaceuticals INC. | $14.37 | 2023 | Trudhesa |
| Octapharma USA, INC. | $14.28 | 2025 | Panzyga |
| Axsome Therapeutics, INC. | $14.20 | 2025 | Symbravo |
| Bausch Health US, LLC | $13.80 | 2019 | |
| Omeros Corporation | $13.79 | 2020 | |
| Neurocrine Biosciences, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.